Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437976 | 0.95 | TSHR (0.44) | TSHRALDH1A1THRBSMN1; SMN2LMNA | |
| SCHEMBL6897883 | 0.93 | TSHR (0.48) | TSHRALDH1A1THRBSMN1; SMN2LMNA | |
| SCHEMBL5968559 | 0.92 | TSHR (0.43) | TSHRALDH1A1LMNA | |
| SCHEMBL8770263 | 0.91 | TSHR (0.41) | TSHRALDH1A1THRBSMN1; SMN2 | |
| SCHEMBL6894712 | 0.87 | TSHR (0.43) | TSHRALDH1A1LMNA | |
| Fluoride SCHEMBL27912823 | 0.85 | TSHR (0.42) | TSHRALDH1A1 | |
| SCHEMBL5881347 | 0.81 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL26666774 | 0.78 | TSHR (0.68) | TSHRALDH1A1LMNAFAAH | |
| SCHEMBL8769664 | 0.78 | TSHR (0.42) | TSHRALDH1A1THRBFAAH | |
| SCHEMBL5968746 | 0.76 | TSHR (0.46) | TSHRALDH1A1THRBFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | claimed |
| EP-3172187-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | claimed |
| EP-3169662-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer CropScience Aktiengesellschaft (DE) | 2017-05-24 | — | — | EP | claimed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | claimed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | claimed |
| WO-2016012362-A1 | SUBSTITUTED CYANO CYCLOALKYL PENTA-2,4-DIENES, CYANO CYCLOALKYL PENT-2-EN-4-YNES, CYANO HETEROCYCLYL PENTA-2,4-DIENES AND CYANO HETEROCYCLYL PENT-2-EN-4-YNES AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | claimed |
| WO-2016008862-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | WO | claimed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | claimed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | claimed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | claimed |
| EP-2697193-A1 | SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | claimed |
| EP-2697194-A1 | SUBSTITUTED 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENTA-2,4-DIENES AND 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENT-2-ENE-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | claimed |
| EP-2697214-A1 | SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | claimed |
| EP-1851240-B1 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | HARVARD COLLEGE (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2012139892-A1 | SUBSTITUTED 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENTA-2,4-DIENES AND 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENT-2-ENE-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | claimed |
| WO-2012139890-A1 | SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | claimed |
| WO-2012139891-A1 | SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | claimed |
| US-20120022013-A1 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | claimed |
| US-6572867-B1 | Reducing plasma levels of anti-( alpha Gal(1,3)Gal) antibodies; nonimmunogenic polymers comprise alpha Gal(1,3) Gal moieties covalently linked to said polymer; cross-links are covalent tethers, derived from N-hydroxysulfosuccinimide | BAXTER INTERNATIONAL INC. | 2003-06-03 | — | — | US | claimed |
| US-11840531-B2 | CDK8/19 inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| WO-2022146201-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2022-07-07 | — | — | WO | disclosed |
| US-20210246138-A1 | CDK8/19 INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2021-08-12 | — | — | US | disclosed |
| EP-3831829-A1 | CDK8/19 INHIBITORS | Joint Stock Company "Biocad" (RU) | 2021-06-09 | — | — | EP | disclosed |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-10-29 | — | — | US | disclosed |
| EP-3693365-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| EP-3666770-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS CDK8/19 INHIBITORS | Joint Stock Company "Biocad" (RU) | 2020-06-17 | — | — | EP | disclosed |
| EP-3169662-B1 | SUBSTITUTED VINYL- AND ALKINYL-CYANOCYCLOALKANOLS AND VINYL- AND ALKINYL-CYANOHETEROCYCLOALKANOLS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-03 | — | — | US | disclosed |
| EP-3169662-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | Bayer CropScience Aktiengesellschaft (DE) | 2017-05-24 | — | — | EP | disclosed |
| CN-106660985-A | Monoamine material for organic electroluminescent element, and organic electroluminescent element using same | 三星显示有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2016024792-A1 | MONOAMINE MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME | 三星ディスプレイ株式會社 | 2016-02-18 | — | — | WO | disclosed |
| US-9241916-B2 | Cognitive performance with sirtuin activators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-26 | — | — | US | disclosed |
| WO-2016008862-A1 | SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | disclosed |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| EP-2805719-A1 | Nicotinamide riboside and analogues thereof | Glaxosmithkline LLC (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8846724-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| EP-2697193-A1 | SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | disclosed |
| EP-2697214-A1 | SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | disclosed |
| EP-2697194-A1 | SUBSTITUTED 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENTA-2,4-DIENES AND 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENT-2-ENE-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | disclosed |
| EP-1851240-B1 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | HARVARD COLLEGE (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2012139892-A1 | SUBSTITUTED 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENTA-2,4-DIENES AND 5-(BICYCLO[4.1.0]HEPT-3-EN-2-YL)-PENT-2-ENE-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012139890-A1 | SUBSTITUTED 5-(CYCLOHEX-2-EN-1-YL)-PENTA-2,4-DIENES AND 5-(CYCLOHEX-2-EN-1-YL)-PENT-2-EN-4-INES AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012139891-A1 | SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-8163938-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120022013-A1 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-8017634-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2361618-A2 | Compositions for treating or preventing obesity and insulin resistance disorders | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2362226-A1 | Diagnostic method for neurodegenerative diseases based on measurement of SIRT1 levels or activity | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7977049-B2 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2298735-A1 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2011-03-23 | — | — | EP | disclosed |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-01-06 | — | — | US | disclosed |
| US-7767830-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2010-08-03 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| CN-100441568-C | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2008-12-10 | — | — | CN | disclosed |
| US-20080194803-A1 | Cognitive Performance With Sirtuin Activators | HOWARD HUGHES MEDICAL INSTITUTE | 2008-08-14 | — | — | US | disclosed |
| EP-1912632-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1877054-A2 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | Sirtris Pharmaceuticals, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1863461-A2 | SIRTUIN RELATED THERAPEUTICS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES | The President and Fellows of Harvard College (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1851240-A2 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | The President and Fellows of Harvard College (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| WO-2007005453-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006138418-A2 | IMPROVEMENT OF COGNITIVE PERFORMANCE WITH SIRTUIN ACTIVATORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060229265-A1 | Nicotinamide riboside and analogues thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| WO-2006105440-A2 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006096780-A2 | SIRTUIN RELATED THERAPEUTICS AND DIAGNOSTICS FOR NEURODEGENERATIVE DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006086454-A2 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1666459-A2 | Aminocyclohexyl ether compounds and uses thereof | Cardiome Pharma Corp. (CA) | 2006-06-07 | — | — | EP | disclosed |
| CN-1780817-A | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2006-05-31 | — | — | CN | disclosed |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-25 | — | — | US | disclosed |
| EP-1560812-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2006-05-10 | — | — | EP | disclosed |
| US-20060094880-A9 | Synthetic process for trans-aminocyclohexyl ether compounds | BARRETT ANTHONY G M | 2006-05-04 | — | — | US | disclosed |
| US-20060025337-A1 | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-02-02 | — | — | US | disclosed |
| US-20050267023-A1 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2005-12-01 | — | — | US | disclosed |
| EP-1560812-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | Cardiome Pharma Corp. (CA) | 2005-08-10 | — | — | EP | disclosed |
| WO-2005016242-A2 | SYNTHETIC PROCESS FOR TRANS-AMINOCYCLOHEXYL ETHER COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2005-02-17 | — | — | US | disclosed |
| WO-2004099137-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2004-11-18 | — | — | WO | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| WO-2004058150-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004052313-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003099801-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6608216-B2 | Preparing biaryl atropisomers; chirality transfer from stereogenic center of secondary alcohol to biaryl stereogenic axis via regioselective intramolecular migration | ABBOTT LABORATORIES | 2003-08-19 | — | — | US | disclosed |
| WO-2003059356-A2 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003037262-A2 | NOVEL ANIT-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20030073844-A1 | Process for the preparation of chiral glucocorticoid receptor agents | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| WO-2003002548-A1 | A PROCESS FOR THE PREPARATION OF CHIRAL GLUCOCORTICOID RECEPTOR AGENTS | ABBOTT LABORATORIES (US) | 2003-01-09 | — | — | WO | disclosed |
| US-6156905-A | Deoxy epothilones and intermediates utilized in the process for preparing epothilones | NOVARTIS AG (CH) | 2000-12-05 | — | — | US | disclosed |
| US-6043372-A | USEFUL CHEMICAL INTERMEDIATES FOR ANTICARCINOGENIC EPITHILONES | NOVARTIS AG (CH) | 2000-03-28 | — | — | US | disclosed |
| US-5969145-A | Process for the production of epothilones and intermediate products within the process | NOVARTIS AG (CH) | 1999-10-19 | — | — | US | disclosed |
| EP-0450585-A2 | Process for the manufacture of 2-deoxy-D-threo-pentofuranosides, intermediates for their manufacture and their use | CHEMPROSA, CHEMISCHE PRODUKTE SAISCHEK GmbH (AT) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450585-A2 | Process for the manufacture of 2-deoxy-D-threo-pentofuranosides, intermediates for their manufacture and their use | CHEMPROSA, CHEMISCHE PRODUKTE SAISCHEK GmbH (AT) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094880-A9 | Synthetic process for trans-aminocyclohexyl ether compounds | AKR1C3, CBR1, CBR3 | TSHR 471/4885ALDH1A1 1484/4885THRB 233/4885 |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | FABP4, PLIN1, SIRT1 | TSHR 3645/4885ALDH1A1 2512/4885THRB 2348/4885 |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | TSHR 3752/4885ALDH1A1 1973/4885THRB 1799/4885 |
| US-20030073844-A1 | Process for the preparation of chiral glucocorticoid receptor agents | NR3C1, NR3C2, MC2R | TSHR 210/4885ALDH1A1 3217/4885THRB 418/4885 |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | TSHR 3782/4885ALDH1A1 1102/4885THRB 3257/4885 |
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | TSHR 4433/4885ALDH1A1 1494/4885THRB 4467/4885 |
| US-11840531-B2 | CDK8/19 inhibitors | CDK8, CDK9, CDK18 | TSHR 3967/4885ALDH1A1 3487/4885THRB 3252/4885 |
| US-20070254945-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | TSHR 3782/4885ALDH1A1 1102/4885THRB 3257/4885 |
| US-20120022013-A1 | METHODS AND COMPOSITIONS FOR EXTENDING THE LIFE SPAN AND INCREASING THE STRESS RESISTANCE OF CELLS AND ORGANISMS | NAMPT, NME1, NMT1 | TSHR 4336/4885ALDH1A1 3217/4885THRB 4056/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | TSHR 2799/4885ALDH1A1 618/4885THRB 1972/4885 |
| US-20060025337-A1 | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases | SIRT1, SIRT2, SIRT3 | TSHR 4462/4885ALDH1A1 2679/4885THRB 3791/4885 |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | AKR1C3, CBR1, CBR3 | TSHR 471/4885ALDH1A1 1484/4885THRB 233/4885 |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | EGFR, ERBB2, ERBB3 | TSHR 192/4885ALDH1A1 3189/4885THRB 159/4885 |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRT1, NAMPT, SIRT2 | TSHR 1983/4885ALDH1A1 1814/4885THRB 1069/4885 |
| US-20210246138-A1 | CDK8/19 INHIBITORS | CDK8, CDK9, CDK18 | TSHR 3967/4885ALDH1A1 3487/4885THRB 3252/4885 |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | TSHR 3752/4885ALDH1A1 1973/4885THRB 1799/4885 |
| US-20050267023-A1 | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms | NAMPT, NME1, NMT1 | TSHR 4336/4885ALDH1A1 3217/4885THRB 4056/4885 |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | TSHR 3782/4885ALDH1A1 1102/4885THRB 3257/4885 |
| US-20060229265-A1 | Nicotinamide riboside and analogues thereof | SIRT1, NAMPT, SIRT2 | TSHR 1983/4885ALDH1A1 1814/4885THRB 1069/4885 |
| US-20080194803-A1 | Cognitive Performance With Sirtuin Activators | SIRT1, SIRT2, SIRT7 | TSHR 3993/4885ALDH1A1 3240/4885THRB 2262/4885 |
| US-20120029065-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | TSHR 3752/4885ALDH1A1 1973/4885THRB 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.